PFIZER INC.
๐บ๐ธUnited States
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2004-05-25
- Last Posted Date
- 2012-08-08
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004200
- Locations
- ๐บ๐ธ
Agouron Pharmaceuticals, Inc., La Jolla, California, United States
Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa
Phase 2
Completed
- Conditions
- Malaria, Falciparum
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 238
- Registration Number
- NCT00082576
- Locations
Pfizer Investigational Site
Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum
Phase 2
Terminated
- Conditions
- Malaria, Falciparum
- First Posted Date
- 2004-05-14
- Last Posted Date
- 2011-04-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 14
- Registration Number
- NCT00082563
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2004-04-19
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00004252
- Locations
- ๐บ๐ธ
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
๐บ๐ธRaleigh Hematology/Oncology Associates - Wake Practice, Raleigh, North Carolina, United States
๐บ๐ธAPN-IMPATH Research Corporation, Fort Lee, New Jersey, United States
Study of the GARFT Inhibitor AG2037 in Patients With Metastatic Colorectal Cancer Who Failed Treatment
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-03-02
- Last Posted Date
- 2006-11-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 56
- Registration Number
- NCT00078468
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, New York, New York, United States
Assessment Of Safety And Efficacy Of SU11248 In Patients With Metastatic Colorectal Cancer Who Have Failed Selected Previous Treatments.
Phase 2
Completed
- Conditions
- Colorectal Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2007-01-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 84
- Registration Number
- NCT00077987
A Study of SU11248 In Patients With Metastatic Breast Cancer Who Have Failed Selected Other Therapies.
Phase 2
Completed
- Conditions
- Breast Neoplasms
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2008-11-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 64
- Registration Number
- NCT00078000
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Boston, Massachusetts, United States
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2010-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 106
- Registration Number
- NCT00077974
- Locations
- ๐บ๐ธ
Pfizer Investigational Site, Madison, Wisconsin, United States
AG-013736 In Combination With Docetaxel Versus Docetaxel Alone For Patients With Metastatic Breast Cancer
Phase 1
Completed
- Conditions
- Breast Neoplasms
- Interventions
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 174
- Registration Number
- NCT00076024
- Locations
- ๐ฌ๐ง
Pfizer Investigational Site, Sheffield, Yorkshire, United Kingdom
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
Phase 2
Completed
- Conditions
- Kidney Neoplasms
- First Posted Date
- 2004-01-14
- Last Posted Date
- 2012-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 52
- Registration Number
- NCT00076011
- Locations
- ๐ฉ๐ช
Pfizer Investigational Site, Hannover, Germany
ยฉ Copyright 2025. All Rights Reserved by MedPath